Why Athersys Stock Jumped Today
The biotech announced the enrollment of the first patient in a key clinical study.
Athersys Inc. is a biopharmaceutical company that is focused in the field of regenerative medicine. It is engaged in the discovery and development of best-in-class therapies designed to extend and enhance the quality of human life.
The biotech announced the enrollment of the first patient in a key clinical study.
ATHX earnings call for the period ending September 30, 2020.
ATHX earnings call for the period ending June 30, 2020.
The stem cell stock jumped after a major Wall Street firm initiated coverage, but there's a catch.
The stem cell stock recovered from a lousy April as the company fed investors updates for its COVID-19 programs.
ATHX earnings call for the period ending March 31, 2020.
The stem cell stock has delivered a 100% gain since the beginning of the year. Can it hold?
Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.
The stem cell developer decided to wisely take advantage of a soaring share price to raise funds.
ATHX earnings call for the period ending September 30, 2019.